从临床试验到真实临床实践:PD-1/PD-L1抑制剂免疫治疗在晚期尿路上皮癌中的作用
本文综述了12篇关于单药PD-1/PD-L1抑制剂治疗晚期尿路上皮癌的临床试验报告,发现缓解率仅17-26%但缓解持久,毒性和疗效特征与标准化疗不同,目前尚缺乏经验证的反应预测生物标志物,最佳用药时长亦未确定。
要点
- PD-1/PD-L1抑制剂在晚期尿路上皮癌中缓解率仅17-26%,但缓解似乎持久。
- 这些药物的毒性和疗效特征与标准化疗方案不同,选择治疗策略时应考虑。
- 目前尚缺乏经验证的反应预测生物标志物,最佳治疗时长亦需进一步研究确定。
核心结论
- PD-1/PD-L1抑制剂是晚期尿路上皮癌管理的重大进步,但其在常规临床实践中的最佳使用仍存在多个问题。
- 目前尚缺乏经验证的反应预测生物标志物,这可能是现有药物最显著的未满足需求。
研究设计与样本
- 本文为综述,检索PubMed中关于单药PD-1/PD-L1抑制剂治疗晚期尿路上皮癌的临床试验全文报告,共纳入12篇文献。
主要发现
- PD-1/PD-L1抑制剂的缓解似乎持久,但仅17-26%的患者获得缓解。
- 这些药物与标准化疗方案的毒性和疗效特征不同,选择每位患者的治疗策略时应考虑这一点。
临床怎么用
- 作者认为,PD-1/PD-L1抑制剂是晚期尿路上皮癌管理的重大进步,但其在常规临床实践中的最佳使用仍存在多个问题。
- 作者指出,目前尚缺乏经验证的反应预测生物标志物,这可能是现有药物最显著的未满足需求。
局限性
- 目前尚缺乏经验证的反应预测生物标志物。
- PD-1/PD-L1抑制剂在常规临床实践中的最佳使用仍存在多个问题。
- 需进一步研究以确定哪些膀胱癌患者会对PD-1/PD-L1抑制剂产生反应。
- 需进一步研究以确定这些药物的最佳治疗时长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: A number of PD-1/PD-L1 inhibitors have recently been approved for use in patients with locally advanced or metastatic urothelial carcinoma (UC) on the basis of results from several clinical trials. OBJECTIVE: To review the evidence from these trials and consider what it means for the use of these drugs in first-line and post-platinum settings in real-life clinical practice. EVIDENCE ACQUISITION: PubMed was searched for full reports of clinical trials of single-agent PD-1/PD-L1 inhibitors in advanced UC. Twelve publications were included. EVIDENCE SYNTHESIS: Responses to PD-1/PD-L1 inhibitors appear to be durable but are only achieved in 17-26% of patients. These drugs offer different toxicity and efficacy profiles to standard chemotherapy regimens. This should be considered when choosing a treatment strategy for each patient. CONCLUSIONS: PD-1/PD-L1 inhibitors represent a major step forward in the management of advanced UC, although several questions remain regarding their optimal use in routine clinical practice. A validated predictive biomarker of response is yet to be defined, and this is perhaps the most significant unmet need for currently available drugs. PATIENT SUMMARY: We reviewed the results from clinical trials that investigated how well certain types of anticancer drugs called PD-1/PD-L1 inhibitors worked in patients with bladder cancer. We found that more research is required to identify (1) the factors that might predict which patients with bladder cancer will respond to PD-1/PD-L1 inhibitors and (2) the optimum duration of treatment with these drugs.
引用
- Hussain SA, Birtle A, Crabb S, et al. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. Eur Urol Oncol. 2018. PMID: 31158093. doi:10.1016/j.euo.2018.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。